C.R. Bard, Inc. (BCR) Stock Rating Reaffirmed by Cowen and Company

C.R. Bard, Inc. (NYSE:BCR)‘s stock had its “hold” rating reiterated by Cowen and Company in a note issued to investors on Friday, November 3rd. They currently have a $317.00 price objective on the medical instruments supplier’s stock. Cowen and Company’s price objective points to a potential downside of 5.42% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on BCR. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. BMO Capital Markets restated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research note on Tuesday, July 11th. Zacks Investment Research lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the company’s stock. C.R. Bard presently has a consensus rating of “Hold” and a consensus target price of $303.50.

C.R. Bard (BCR) traded down $1.48 on Friday, reaching $335.18. 551,895 shares of the company traded hands, compared to its average volume of 660,728. C.R. Bard has a 52-week low of $206.26 and a 52-week high of $336.98. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $24,294.30, a price-to-earnings ratio of 28.78, a price-to-earnings-growth ratio of 2.55 and a beta of 0.53.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The business’s revenue was up 5.1% on a year-over-year basis. During the same period last year, the firm posted $2.64 earnings per share. equities analysts anticipate that C.R. Bard will post 11.89 EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was first reported by BBNS and is owned by of BBNS. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://baseballnewssource.com/markets/c-r-bard-inc-bcr-given-hold-rating-at-cowen-and-company/1756580.html.

In other news, Director David M. Barrett sold 3,344 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $327.31, for a total value of $1,094,524.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Vice Chairman John H. Weiland sold 33,435 shares of the stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $333.31, for a total transaction of $11,144,219.85. Following the completion of the transaction, the insider now directly owns 76,331 shares of the company’s stock, valued at approximately $25,441,885.61. The disclosure for this sale can be found here. Insiders have sold 191,593 shares of company stock worth $62,655,513 over the last quarter. Corporate insiders own 0.80% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Monroe Bank & Trust MI grew its position in shares of C.R. Bard by 65.6% during the 3rd quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock worth $100,000 after buying an additional 177 shares during the period. Patten Group Inc. grew its position in shares of C.R. Bard by 66.0% during the 3rd quarter. Patten Group Inc. now owns 556 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 221 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in C.R. Bard by 70.4% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after purchasing an additional 190 shares during the period. Parallel Advisors LLC grew its position in C.R. Bard by 2.8% in the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after purchasing an additional 14 shares during the period. Finally, Valeo Financial Advisors LLC acquired a new stake in C.R. Bard in the 3rd quarter valued at $170,000. Hedge funds and other institutional investors own 80.31% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.